TY - JOUR
T1 - Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers
AU - Handels, Ron L.H.
AU - Vos, Stephanie J.B.
AU - Kramberger, Milica G.
AU - Jelic, Vesna
AU - Blennow, Kaj
AU - van Buchem, Mark
AU - van der Flier, Wiesje
AU - Freund-Levi, Yvonne
AU - Hampel, Harald
AU - Olde Rikkert, Marcel
AU - Oleksik, Ania
AU - Pirtosek, Zvezdan
AU - Scheltens, Philip
AU - Soininen, Hilkka
AU - Teunissen, Charlotte
AU - Tsolaki, Magda
AU - Wallin, Asa K.
AU - Winblad, Bengt
AU - Verhey, Frans R.J.
AU - Visser, Pieter Jelle
PY - 2017/8/1
Y1 - 2017/8/1
N2 - Introduction We aimed to determine the added value of cerebrospinal fluid (CSF) to clinical and imaging tests to predict progression from mild cognitive impairment (MCI) to any type of dementia. Methods The risk of progression to dementia was estimated using two logistic regression models based on 250 MCI participants: the first included standard clinical measures (demographic, clinical, and imaging test information) without CSF biomarkers, and the second included standard clinical measures with CSF biomarkers. Results Adding CSF improved predictive accuracy with 0.11 (scale from 0–1). Of all participants, 136 (54%) had a change in risk score of 0.10 or higher (which was considered clinically relevant), of whom in 101, it was in agreement with their dementia status at follow-up. Discussion An individual person's risk of progression from MCI to dementia can be improved by relying on CSF biomarkers in addition to recommended clinical and imaging tests for usual care.
AB - Introduction We aimed to determine the added value of cerebrospinal fluid (CSF) to clinical and imaging tests to predict progression from mild cognitive impairment (MCI) to any type of dementia. Methods The risk of progression to dementia was estimated using two logistic regression models based on 250 MCI participants: the first included standard clinical measures (demographic, clinical, and imaging test information) without CSF biomarkers, and the second included standard clinical measures with CSF biomarkers. Results Adding CSF improved predictive accuracy with 0.11 (scale from 0–1). Of all participants, 136 (54%) had a change in risk score of 0.10 or higher (which was considered clinically relevant), of whom in 101, it was in agreement with their dementia status at follow-up. Discussion An individual person's risk of progression from MCI to dementia can be improved by relying on CSF biomarkers in addition to recommended clinical and imaging tests for usual care.
KW - Alzheimer's disease
KW - Conversion
KW - Dementia
KW - Mild cognitive impairment
KW - Predict
KW - Prognosis
KW - Progression
KW - Reclassification
KW - Risk
KW - Risk prediction model
UR - http://www.scopus.com/inward/record.url?scp=85014793039&partnerID=8YFLogxK
U2 - 10.1016/j.jalz.2016.12.015
DO - 10.1016/j.jalz.2016.12.015
M3 - Article
C2 - 28216393
AN - SCOPUS:85014793039
VL - 13
SP - 903
EP - 912
JO - Alzheimers & Dementia
JF - Alzheimers & Dementia
SN - 1552-5260
IS - 8
ER -